1. Others Membrane Transporter/Ion Channel Autophagy Metabolic Enzyme/Protease
  2. Autophagy Environmental Pollutants P-glycoprotein Endogenous Metabolite
  3. Piperine

ピペリン  (Synonyms: Piperine; Bioperine; 1-Piperoylpiperidine)

製品番号: HY-N0144 純度: 98.99%
COA 取扱説明書 Technical Support

Piperine is an alkaloid, can be isolated from pepper. Piperine can inhibit the activity of P-glycoprotein and CYP3A4. Piperine inhibits HeLa cells with an IC50 of 61.94±0.054 μg/mL.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 94-62-2

容量 価格(税別) 在庫状況 数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 33 在庫あり
Solution
10 mM * 1 mL in DMSO USD 33 在庫あり
Solid
5 g $30 在庫あり
10 g $50 在庫あり
25 g $110 在庫あり
50 g $155 在庫あり
100 g $250 在庫あり
> 100 g   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 17 publication(s) in Google Scholar

Other Forms of Piperine:

Top Publications Citing Use of Products

    Piperine purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2018 Dec:65:448-457.  [Abstract]

    Piperine inhibits the activation of NLRP3 inflammasome. The protein levels of indicated targets are examined by Western blot.

    Piperine purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2018 Dec:65:448-457.  [Abstract]

    Piperine targets NLRP3 inflammasome in HK-2 cells. The protein levels of indicated proteins in cell lysates and from culture medium are examined by Western blot.

    Piperine purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2018 Dec:65:448-457.  [Abstract]

    Piperine inhibits AMPK activation. HK-2 cells are treated as indicated and the levels of p-AMPK, total AMPK, and β-tubulin are examined by Western blot.

    Piperine purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2018 Dec:65:448-457.  [Abstract]

    Piperine targets NLRP3 inflammasome by blocking AMPK activation. HK-2 cells are treated as indicated.

    Endogenous Metabolite アイソフォーム固有の製品をすべて表示:

    • 生物活性

    • プロトコル

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Piperine is an alkaloid, can be isolated from pepper. Piperine can inhibit the activity of P-glycoprotein and CYP3A4. Piperine inhibits HeLa cells with an IC50 of 61.94±0.054 μg/mL[1][2][3].

    IC50 & Target

    IC50: 61.94±0.054 μg/mL (P-glycoprotein, HeLa cell)[1]

    Cellular Effect
    Cell Line Type Value Description References
    A549 IC50
    11.89 3
    Compound: Piperine
    Antiproliferative activity in human A549 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    Antiproliferative activity in human A549 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    [PMID: 30108756]
    A549 IC50
    11.89 3
    Compound: Piperine
    Antiproliferative activity in human A549 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    Antiproliferative activity in human A549 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    [PMID: 30108756]
    Bel-7402 IC50
    >10 3
    Compound: Piperine
    Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 33026807]
    Bel-7402 IC50
    > 10 3
    Compound: Piperine
    Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 33026807]
    BTI-TN-5B1-4 IC50
    1.05 3
    Compound: 1
    Inhibition of human microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as reduction in 4-hydroxyquinoline formation using kynuramine as substrate preincubated with substrate for 10 mins followed by enzyme addition by spectropho
    Inhibition of human microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as reduction in 4-hydroxyquinoline formation using kynuramine as substrate preincubated with substrate for 10 mins followed by enzyme addition by spectropho
    [PMID: 31711793]
    BTI-TN-5B1-4 IC50
    1.05 3
    Compound: 1
    Inhibition of human microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as reduction in 4-hydroxyquinoline formation using kynuramine as substrate preincubated with substrate for 10 mins followed by enzyme addition by spectropho
    Inhibition of human microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as reduction in 4-hydroxyquinoline formation using kynuramine as substrate preincubated with substrate for 10 mins followed by enzyme addition by spectropho
    [PMID: 31711793]
    COLO 205 IC50
    46 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) COLO205 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) COLO205 cells by SRB assay
    10.1007/s00044-010-9500-5
    DLD-1 IC50
    < 200 3
    Compound: 58
    Anticancer activity against human DLD-1 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Anticancer activity against human DLD-1 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    [PMID: 33445154]
    A549 IC50
    11.89 3
    Compound: Piperine
    Antiproliferative activity in human A549 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    Antiproliferative activity in human A549 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    [PMID: 30108756]
    BTI-TN-5B1-4 IC50
    1.05 3
    Compound: 1
    Inhibition of human microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as reduction in 4-hydroxyquinoline formation using kynuramine as substrate preincubated with substrate for 10 mins followed by enzyme addition by spectropho
    Inhibition of human microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as reduction in 4-hydroxyquinoline formation using kynuramine as substrate preincubated with substrate for 10 mins followed by enzyme addition by spectropho
    [PMID: 31711793]
    DU-145 IC50
    > 50 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) DU145 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) DU145 cells by SRB assay
    10.1007/s00044-010-9500-5
    COLO 205 IC50
    46 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) COLO205 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) COLO205 cells by SRB assay
    10.1007/s00044-010-9500-5
    HCT-116 IC50
    < 200 3
    Compound: 58
    Anticancer activity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Anticancer activity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    [PMID: 33445154]
    DLD-1 IC50
    <200 3
    Compound: 58
    Anticancer activity against human DLD-1 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Anticancer activity against human DLD-1 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    [PMID: 33445154]
    HeLa IC50
    0.95 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay
    10.1007/s00044-013-0541-4
    DU-145 IC50
    >50 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) DU145 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) DU145 cells by SRB assay
    10.1007/s00044-010-9500-5
    Bel-7402 IC50
    > 10 3
    Compound: Piperine
    Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 33026807]
    HeLa IC50
    19.21 3
    Compound: Piperine
    Antiproliferative activity in human HeLa cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    Antiproliferative activity in human HeLa cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    [PMID: 30108756]
    HCT-116 IC50
    <200 3
    Compound: 58
    Anticancer activity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Anticancer activity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    [PMID: 33445154]
    HEp-2 IC50
    70 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) Hep2 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) Hep2 cells by SRB assay
    10.1007/s00044-010-9500-5
    HeLa IC50
    19.21 3
    Compound: Piperine
    Antiproliferative activity in human HeLa cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    Antiproliferative activity in human HeLa cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    [PMID: 30108756]
    COLO 205 IC50
    46 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) COLO205 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) COLO205 cells by SRB assay
    10.1007/s00044-010-9500-5
    Hepatocyte IC50
    12 3
    Compound: 10
    Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cytotoxicity after 20 hrs by MTT assay relative to untreated control
    Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cytotoxicity after 20 hrs by MTT assay relative to untreated control
    [PMID: 19775895]
    HeLa IC50
    0.95 87
    Compound: 1
    Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay
    10.1007/s00044-013-0541-4
    Caco-2 IC50
    15.5 3
    Compound: Piperine
    TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells
    TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells
    [PMID: 12130727]
    HEp-2 IC50
    70 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) Hep2 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) Hep2 cells by SRB assay
    10.1007/s00044-010-9500-5
    HepG2 IC50
    > 10 3
    Compound: Piperine
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 33026807]
    HUVEC IC50
    100 3
    Compound: Piperine
    Antiinflammatory activity in HUVEC assessed as inhibition of TNFalpha-induced ICAM-1 expression incubated for 2 hrs prior to TNFalpha challenge measured after 16 hrs by ELISA
    Antiinflammatory activity in HUVEC assessed as inhibition of TNFalpha-induced ICAM-1 expression incubated for 2 hrs prior to TNFalpha challenge measured after 16 hrs by ELISA
    10.1039/C2MD20216F
    Hepatocyte IC50
    12 3
    Compound: 10
    Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cytotoxicity after 20 hrs by MTT assay relative to untreated control
    Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cytotoxicity after 20 hrs by MTT assay relative to untreated control
    [PMID: 19775895]
    Caco-2 IC50
    74.1 3
    Compound: Piperine
    TP_TRANSPORTER: inhibition of Cyclosporin A transepithelial transport (basal to apical) (Cyclosporin A: 1 uM) in Caco-2 cells
    TP_TRANSPORTER: inhibition of Cyclosporin A transepithelial transport (basal to apical) (Cyclosporin A: 1 uM) in Caco-2 cells
    [PMID: 12130727]
    IMR-32 IC50
    10.19 3
    Compound: Piperine
    Antiproliferative activity in human IMR32 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    Antiproliferative activity in human IMR32 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    [PMID: 30108756]
    HepG2 IC50
    >10 3
    Compound: Piperine
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 33026807]
    DLD-1 IC50
    < 200 3
    Compound: 58
    Anticancer activity against human DLD-1 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Anticancer activity against human DLD-1 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    [PMID: 33445154]
    IMR-32 IC50
    89 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) IMR32 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) IMR32 cells by SRB assay
    10.1007/s00044-010-9500-5
    DU-145 IC50
    > 50 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) DU145 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) DU145 cells by SRB assay
    10.1007/s00044-010-9500-5
    L929 IC50
    42 3
    Compound: 10
    Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity by MTT assay relative to untreated control
    Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity by MTT assay relative to untreated control
    [PMID: 19775895]
    MCF7 IC50
    0.99 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by MTT assay
    10.1007/s00044-013-0541-4
    HCT-116 IC50
    < 200 3
    Compound: 58
    Anticancer activity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Anticancer activity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    [PMID: 33445154]
    MCF7 IC50
    12.96 3
    Compound: Piperine
    Antiproliferative activity in human MCF7 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    Antiproliferative activity in human MCF7 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    [PMID: 30108756]
    HUVEC IC50
    100 3
    Compound: Piperine
    Antiinflammatory activity in HUVEC assessed as inhibition of TNFalpha-induced ICAM-1 expression incubated for 2 hrs prior to TNFalpha challenge measured after 16 hrs by ELISA
    Antiinflammatory activity in HUVEC assessed as inhibition of TNFalpha-induced ICAM-1 expression incubated for 2 hrs prior to TNFalpha challenge measured after 16 hrs by ELISA
    10.1039/C2MD20216F
    MCF7 IC50
    99 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) MCF7 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) MCF7 cells by SRB assay
    10.1007/s00044-010-9500-5
    HEp-2 IC50
    70 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) Hep2 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) Hep2 cells by SRB assay
    10.1007/s00044-010-9500-5
    IMR-32 IC50
    10.19 3
    Compound: Piperine
    Antiproliferative activity in human IMR32 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    Antiproliferative activity in human IMR32 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    [PMID: 30108756]
    MDA-MB-231 IC50
    58.45 6
    Compound: 3
    Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition by MTT assay
    Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition by MTT assay
    10.1007/s00044-012-0397-z
    IMR-32 IC50
    89 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) IMR32 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) IMR32 cells by SRB assay
    10.1007/s00044-010-9500-5
    Oocyte EC50
    52 3
    Compound: 5
    Activation of rat GABA alpha-1-beta-2-gamma-2 receptor expressed in xenopus oocytes assessed as potentiation of GABA-induced chloride current after 90 secs by two microplate electrode voltage clamp assay
    Activation of rat GABA alpha-1-beta-2-gamma-2 receptor expressed in xenopus oocytes assessed as potentiation of GABA-induced chloride current after 90 secs by two microplate electrode voltage clamp assay
    [PMID: 20085307]
    L929 IC50
    42 3
    Compound: 10
    Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity by MTT assay relative to untreated control
    Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity by MTT assay relative to untreated control
    [PMID: 19775895]
    PC-3 IC50
    > 50 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) PC3 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) PC3 cells by SRB assay
    10.1007/s00044-010-9500-5
    MCF7 IC50
    12.96 3
    Compound: Piperine
    Antiproliferative activity in human MCF7 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    Antiproliferative activity in human MCF7 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    [PMID: 30108756]
    SW480 IC50
    < 200 3
    Compound: 58
    Anticancer activity against human SW480 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Anticancer activity against human SW480 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    [PMID: 33445154]
    MCF7 IC50
    0.99 87
    Compound: 1
    Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by MTT assay
    10.1007/s00044-013-0541-4
    MCF7 IC50
    99 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) MCF7 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) MCF7 cells by SRB assay
    10.1007/s00044-010-9500-5
    HUVEC IC50
    100 3
    Compound: Piperine
    Antiinflammatory activity in HUVEC assessed as inhibition of TNFalpha-induced ICAM-1 expression incubated for 2 hrs prior to TNFalpha challenge measured after 16 hrs by ELISA
    Antiinflammatory activity in HUVEC assessed as inhibition of TNFalpha-induced ICAM-1 expression incubated for 2 hrs prior to TNFalpha challenge measured after 16 hrs by ELISA
    10.1039/C2MD20216F
    MDA-MB-231 IC50
    58.45 6
    Compound: 3
    Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition by MTT assay
    Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition by MTT assay
    10.1007/s00044-012-0397-z
    Oocyte EC50
    52 3
    Compound: 5
    Activation of rat GABA alpha-1-beta-2-gamma-2 receptor expressed in xenopus oocytes assessed as potentiation of GABA-induced chloride current after 90 secs by two microplate electrode voltage clamp assay
    Activation of rat GABA alpha-1-beta-2-gamma-2 receptor expressed in xenopus oocytes assessed as potentiation of GABA-induced chloride current after 90 secs by two microplate electrode voltage clamp assay
    [PMID: 20085307]
    PC-3 IC50
    >50 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) PC3 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) PC3 cells by SRB assay
    10.1007/s00044-010-9500-5
    HeLa IC50
    0.95 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay
    10.1007/s00044-013-0541-4
    SW480 IC50
    <200 3
    Compound: 58
    Anticancer activity against human SW480 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Anticancer activity against human SW480 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    [PMID: 33445154]
    HeLa IC50
    19.21 3
    Compound: Piperine
    Antiproliferative activity in human HeLa cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    Antiproliferative activity in human HeLa cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    [PMID: 30108756]
    HepG2 IC50
    > 10 3
    Compound: Piperine
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 33026807]
    HepG2 2.2.15 CC50
    2.35 2
    Compound: 7
    Cytotoxicity against human HepG2(2.2.15) cells
    Cytotoxicity against human HepG2(2.2.15) cells
    [PMID: 23434420]
    HepG2 2.2.15 IC50
    0.14 2
    Compound: 7
    Antiviral activity against Hepatitis B virus-infected human HepG2(2.2.15) cells assessed as inhibition of HBeAg secretion
    Antiviral activity against Hepatitis B virus-infected human HepG2(2.2.15) cells assessed as inhibition of HBeAg secretion
    [PMID: 23434420]
    HepG2 2.2.15 IC50
    0.15 2
    Compound: 7
    Antiviral activity against Hepatitis B virus-infected human HepG2(2.2.15) cells assessed as inhibition of HBsAg secretion
    Antiviral activity against Hepatitis B virus-infected human HepG2(2.2.15) cells assessed as inhibition of HBsAg secretion
    [PMID: 23434420]
    Hepatocyte IC50
    12 3
    Compound: 10
    Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cytotoxicity after 20 hrs by MTT assay relative to untreated control
    Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cytotoxicity after 20 hrs by MTT assay relative to untreated control
    [PMID: 19775895]
    IMR-32 IC50
    10.19 3
    Compound: Piperine
    Antiproliferative activity in human IMR32 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    Antiproliferative activity in human IMR32 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    [PMID: 30108756]
    IMR-32 IC50
    89 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) IMR32 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) IMR32 cells by SRB assay
    10.1007/s00044-010-9500-5
    L929 IC50
    42 3
    Compound: 10
    Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity by MTT assay relative to untreated control
    Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity by MTT assay relative to untreated control
    [PMID: 19775895]
    MCF7 IC50
    0.99 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by MTT assay
    10.1007/s00044-013-0541-4
    MCF7 IC50
    12.96 3
    Compound: Piperine
    Antiproliferative activity in human MCF7 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    Antiproliferative activity in human MCF7 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay
    [PMID: 30108756]
    MCF7 IC50
    99 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) MCF7 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) MCF7 cells by SRB assay
    10.1007/s00044-010-9500-5
    MDA-MB-231 IC50
    58.45 6
    Compound: 3
    Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition by MTT assay
    Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition by MTT assay
    10.1007/s00044-012-0397-z
    Oocyte EC50
    52 3
    Compound: 5
    Activation of rat GABA alpha-1-beta-2-gamma-2 receptor expressed in xenopus oocytes assessed as potentiation of GABA-induced chloride current after 90 secs by two microplate electrode voltage clamp assay
    Activation of rat GABA alpha-1-beta-2-gamma-2 receptor expressed in xenopus oocytes assessed as potentiation of GABA-induced chloride current after 90 secs by two microplate electrode voltage clamp assay
    [PMID: 20085307]
    PC-3 IC50
    > 50 3
    Compound: 1
    Cytotoxicity against Homo sapiens (human) PC3 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) PC3 cells by SRB assay
    10.1007/s00044-010-9500-5
    SW480 IC50
    < 200 3
    Compound: 58
    Anticancer activity against human SW480 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Anticancer activity against human SW480 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    [PMID: 33445154]
    WI-38 IC50
    8.8 3
    Compound: 2
    Induction of senescence in human WI-38 cells
    Induction of senescence in human WI-38 cells
    [PMID: 38436272]
    体外実験

    Piperine has shown to possess in vitro cytotoxic activity and in silico studies. The IC50 value is found to be 61.94±0.054 μg/mL and in silico studies, it has more number of hydrogen bonds with minimum binding and docking energy and may be considered as inhibitor of EGFR tyrosine kinase[1]. Piperine has been found to have immunomodulatory, anti-oxidant, anti-asthmatic, anti-carcinogenic, anti-inflammatory, anti-ulcer, and anti-amoebic properties[2]. Piperine could enhance the bioavailabilities of other drugs including rosuvastatin, peurarin and docetaxel (DOX) via inhibition of CYP3A and P-glycoprotein activity[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    体内実験

    At the dose of 3.5 mg/kg, the bioavailability of piperine is calculated to be 25.36%. Its AUC0→t is unproportionally increased with doses, indicating a potential non-linear pharmacokinetics profile of piperine. It is found that the AUC0→t and C0 of Docetaxel (HY-B0011) and t1/2 of piperine are significantly increased after their combination use, suggesting potential enhanced bioavailability of not only Docetaxel but also Piperine, which may lead to the overall enhanced pharmacological effects[3]. The phosphorylation of I-κB, p65, p38, ERK, and JNK is inhibited by piperine in a dose-dependent manner, indicating that piperine may be a potential anti-inflammatory drug both in endometritis and in other S. aureus-induced diseases[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    臨床実験
    分子量

    285.34

    分子式

    C17H19NO3

    CAS 番号
    Appearance

    Solid

    Color

    White to light yellow

    SMILES

    O=C(N1CCCCC1)/C=C/C=C/C2=CC=C(OCO3)C3=C2

    Structure Classification
    Initial Source
    輸送条件

    Room temperature in continental US; may vary elsewhere.

    保管条件
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    溶剤 & 溶解度
    体外: 

    DMSO : 50 mg/mL (175.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.5046 mL 17.5230 mL 35.0459 mL
    5 mM 0.7009 mL 3.5046 mL 7.0092 mL
    10 mM 0.3505 mL 1.7523 mL 3.5046 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます:C1V1 = C2V2

    濃度 (開始)

    C1

    ×
    体積 (開始)

    V1

    =
    濃度 (終了)

    C2

    ×
    体積 (終了)

    V2

    体内:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (8.76 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (8.76 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    純度とドキュメンテーション

    純度: 98.99%

    参考文献
    細胞実験
    [1]

    Standard solution is prepared by dissolving 10 mg of piperine in 100 mL of methanol. The MTT assay is carried out to measure cell viability. Ten thousand cells in 100 μL of DMEM media are seeded in the wells of a 96-well plate. After 24 h, existing media is removed and 100 μL of various concentrations of piperine (20–100 μg/mL) are added and incubated for 48 h at 37 °C in a CO2 incubator. Control cells are supplemented with 0.05 % DMSO vehicle. At the 48th hour of incubation, MTT (10 μL of 5 mg/mL) is added to the plate. The contents of the plate are pipetted out carefully, the formazan crystals formed are dissolved in 100 μL of DMSO, and the absorbance is measured at 550 nm in a microplate reader[1].

    MedChemExpress (MCE) はこれらの方法の精度を確認していません。 こちらは参照専用です。

    動物実験
    [3][4]

    Rats: The stock solutions of piperine (PIP) and docetaxel (DOX)are prepared by dissolving appropriate amount of each authentic compound in DMSO separately at 1 mg/mL. The standard solutions containing both PIP and DOX are prepared by serial dilution of the stock solutions with 0.2% formic acid and acetonitrile (50:50, v/v) to yield concentrations of 25, 50, 100, 200, 400, 800, 1600, 3200, 6400, 12800 ng/mL. 25 Sprague-Dawley rats are divided into five groups receiving DOX(Group DOX 7 iv, 7 mg/kg, i.v.), PIP (Group PIP 35 po, 35 mg/kg,p.o.) and their combined administration (Group DOX+PIP) as well as PIP (Group PIP 3.5 po, 3.5 mg/kg, p.o.) and PIP (Group PIP 3.5 iv, 3.5 mg/kg, i.v.)[3].

    Mice: Piperine is dissolved in 5 mL of tris buffered saline (TBS) at concentrations corresponding to 25, 50, and 100 mg/kg, based on the weight of the mice. After 24 h of S. aureus infection in the uterus, the piperine solution is injected intraperitoneally three times every 6 h. A total of 60 female BALB/c mice are used in this study. All mice are maintained on a 12 h light/dark cycle and cafeteria feeding[4].

    MedChemExpress (MCE) はこれらの方法の精度を確認していません。 こちらは参照専用です。

    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.5046 mL 17.5230 mL 35.0459 mL 87.6148 mL
    5 mM 0.7009 mL 3.5046 mL 7.0092 mL 17.5230 mL
    10 mM 0.3505 mL 1.7523 mL 3.5046 mL 8.7615 mL
    15 mM 0.2336 mL 1.1682 mL 2.3364 mL 5.8410 mL
    20 mM 0.1752 mL 0.8761 mL 1.7523 mL 4.3807 mL
    25 mM 0.1402 mL 0.7009 mL 1.4018 mL 3.5046 mL
    30 mM 0.1168 mL 0.5841 mL 1.1682 mL 2.9205 mL
    40 mM 0.0876 mL 0.4381 mL 0.8761 mL 2.1904 mL
    50 mM 0.0701 mL 0.3505 mL 0.7009 mL 1.7523 mL
    60 mM 0.0584 mL 0.2920 mL 0.5841 mL 1.4602 mL
    80 mM 0.0438 mL 0.2190 mL 0.4381 mL 1.0952 mL
    100 mM 0.0350 mL 0.1752 mL 0.3505 mL 0.8761 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます:C1V1 = C2V2

    濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

     

    カスタマ需要量 *

    お名前 *

     

    タイトル

    メールアドレス *

     

    電話番号 *

    デパートメント

     

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

         

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Piperine
    製品番号:
    HY-N0144
    数量:
    MCE 日本正規代理店: